Neutral
Accesswire
1 year ago
Biotricity Reports Strong Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses for Fiscal Year 2024, Accelerating the Company's Path to Profitability
FY24 revenue up 25.2% YOY FY24 margins improved 1280 basis points to 69.3%, from 56.5% in the prior year; Q4-FY24 margins improved to 71.5%; margin expansion forecasted to continue FY24 operating expenses lower by 17.6% YOY Negative EBITDA reduced by $7.2 million - an improvement of 44.6% -- accelerating the Company's path to breakeven and EBITDA positive REDWOOD CITY, CA / ACCESSWIRE / June 27, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the fourth quarter and fiscal year ended March 31, 2024. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "Fiscal 2024 has been a year of massive transformation for Biotricity.